Kyverna Therapeutics (KYTX) Q1 2026 earnings summary

Executive summary

• Focused on late-stage clinical development of cell therapies for autoimmune diseases, with lead candidate mivocabtagene autoleucel (miv-cel) advancing in SPS and gMG indications; initiated rolling BLA submission for SPS after FDA alignment on pivotal trial sufficiency.

• Positive Phase 2 and pivotal trial data in SPS and gMG, with robust, durable efficacy and favorable safety; all SPS patients remained off immunotherapies at 16 weeks.

• Enrollment ongoing in Phase 3 trial for gMG, with Phase 2 data showing durable, drug-free remission out to one year.

• Received RMAT and Orphan Drug Designations for key programs, strengthened CMC capabilities, and appointed new Chief Commercial and Technology Officers to support commercialization.

• Positive follow-up data in progressive multiple sclerosis (PMS) from investigator-initiated trial, with all patients showing improvement or stability in disability scores.

Financial highlights

• Ended Q1 2026 with $236.4 million in cash, cash equivalents, and marketable securities, expected to fund operations for at least 12 months and potentially into 2028.

• Net loss for Q1 2026 was $39.7 million, or $0.66 per share, improved from $44.6 million or $1.03 per share in Q1 2025.

• Research and development expenses were $30.1 million, down 20% year-over-year, and general and administrative expenses increased 13% to $11.3 million.

• Interest income declined 18% to $2.3 million; interest expense rose to $0.7 million due to new term loan.

• Accumulated deficit reached $464.6 million as of March 31, 2026.

Outlook and guidance

• Expects to complete rolling BLA submission for SPS in Q4 2026 and seeks priority review under RMAT designation.

• Plans to share one-year follow-up data for SPS and longer-term Phase 2 data for gMG in the second half of 2026.

• Management expects continued operating losses and negative cash flows as development and clinical activities expand.

• Existing cash and available credit facilities expected to fund operations for at least one year from the filing date.

• Manufacturing capacity expected to fully support commercial launch of miv-cel.